Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

335
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
335

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metapath-guided transfer learning with clinical validation for identifying herb-drug interactions.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

Tomentosin selectively targets microglial pyroptosis to overcome fluoxetine-resistant depression: a network-based therapeutic discovery.

Translational psychiatry·2026
Same author

Targeting the NLRP3 Inflammasome in Atherosclerosis: A Review of Natural Products and Their Molecular Mechanisms.

International journal of molecular sciences·2026
Same author

The absence of basement membrane in overlapped acellular dermal matrix promotes tissue integration in implant-based breast reconstruction.

Plastic and reconstructive surgery·2026
Same author

Ferroportin is a candidate regulator of dendritic cell-mediated immune tolerance.

Immunology letters·2026
Same author

Transcutaneous auricular vagus nerve stimulation promotes recovery from otitis media by activating the α7nAChR-mediated anti-inflammatory pathway.

Inflammation and regeneration·2026

Related Experiment Video

Updated: Mar 29, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K

Multiscale Interactome-Guided Prioritization of Candidate Herbs and Active Compounds for Hepatic Cirrhosis Using a

Jun-Ho Lee1, Seon-Been Bak2,3, Won-Yung Lee4,5

  • 1College of Herbal Medicine, Wonkwang University, Iksan 54538, Republic of Korea.

Current Issues in Molecular Biology
|March 28, 2026
PubMed
Summary

This study identifies promising herbal treatments for hepatic cirrhosis using a network biology approach. It prioritizes candidate herbs and compounds, offering new avenues for treating this chronic liver disease.

Keywords:
active compoundshepatic cirrhosisherbal candidatesmultiscale network analysis

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K

Related Experiment Videos

Last Updated: Mar 29, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K

Area of Science:

  • Integrative biology
  • Network pharmacology
  • Traditional Chinese Medicine research

Background:

  • Hepatic cirrhosis is a chronic liver disease with limited treatment options.
  • Sustained inflammation, cell death, and tissue remodeling drive disease progression.
  • Novel therapeutic strategies are urgently needed for hepatic cirrhosis management.

Purpose of the Study:

  • To systematically prioritize candidate herbs and active compounds for hepatic cirrhosis using a multiscale interactome framework.
  • To identify novel, evidence-lacking herbal candidates for further investigation.
  • To elucidate potential mechanisms of action for prioritized compounds.

Main Methods:

  • Integrated herb-compound associations (OASIS) with compound-target interactions (DrugBank/TTD/STITCH) and cirrhosis proteins (DisGeNET).
  • Applied a biased random-walk algorithm on a multiscale network to rank candidates by diffusion profile similarity and target overlap.
  • Performed pathway enrichment analyses and constructed disease-focused subnetworks.

Main Results:

  • Prioritized several herbs, including Magnoliae Cortex and Notoginseng Radix et Rhizoma, with existing literature support.
  • Highlighted underexplored candidates like Saposhnikoviae Radix and Fritillariae Cirrhosae Bulbus.
  • Identified key pathways involved, including TNF, Toll-like receptor, NF-κB, HIF-1, and PI3K-Akt signaling, and proposed mechanisms for compounds like bergapten.

Conclusions:

  • This study provides a systematic, data-driven prioritization of herbal candidates for hepatic cirrhosis.
  • It offers a mechanistic foundation for validating novel herbal therapies.
  • The findings pave the way for developing new disease-modifying treatments for hepatic cirrhosis.